Price movement over the last 24 hours
ADMA Biologics Inc vs United States Oil ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while United States Oil ETF trades at $113.16. The key difference: United States Oil ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | USO | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $152.96 |
52-Week Low | $7.60 | $66.17 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
USO (United States Oil Fund) trades at $104.35, showing modest daily gains of 0.36% amid heightened geopolitical tensions in the Middle East. Technical indicators signal a bearish trend with moving averages showing strong sell signals, though oscillators remain neutral. The fund's price action reflects direct exposure to crude oil volatility, with recent U.S. military strikes against Iran and attacks in the Strait of Hormuz driving supply disruption fears and price increases.
The outlook remains heavily dependent on geopolitical developments and oil supply dynamics. While recent Middle East tensions provide upward price pressure, risks include potential supply increases from Gulf producers and weak demand signals that could limit sustained recovery. The fund offers direct commodity exposure but faces contango risks and tracking error inherent to futures-based ETFs.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →